GoAI
Get started
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc.

XLO

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$9.2186

−$0.0114 · -0.12%

Aug 24, 12:02 PM ETData delayed

XLO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

88

Deep Value

Momentum

43

Neutral

Sentiment

45

Mixed

Risk resilience

55

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Rene Russo
Listed since
Oct 22, 2021
Employees
76

Market position

Day range

Current $9.2186

52-week range

Current $9.2186

Open
$9.32
Previous close
$9.23
Volume
1.14K
0.03× average
Average volume
41.32K
Average daily volume
Market cap
60.61M USD
Beta
-0.12
Market reference 1
50-day average
$9.0094
+2.32% above average
200-day average
$8.7913
+4.86% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
618.4M USD
EV / EBITDA
-18.46×
Earnings yield
-4.68%
Free cash flow yield
-0.74%

Profitability & efficiency

Return on equity
-99.33%
Return on assets
-22.65%
Return on invested capital
-42.09%

Financial health

Current ratio
2.58×
Altman Z-score
-2.69
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends205%-216%-638%-1060%Gross margin, FY2024: 100.00%Gross margin, FY2025: 96.48%Operating margin, FY2024: -954.95%Operating margin, FY2025: -95.92%Net margin, FY2024: -918.05%Net margin, FY2025: -80.05%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 100.00%. Gross margin FY2025 96.48%. Operating margin FY2024 -954.95%. Operating margin FY2025 -95.92%. Net margin FY2024 -918.05%. Net margin FY2025 -80.05%.

Income trends

Revenue

43.77M USD+589.88%

Operating income

−41.98M USD+30.70%

Net income

−35.04M USD+39.84%
Income trends across reported periods57.06M USD3.89M USD−49.27M USD−102.44M USDRevenue, FY2024: 6.34M USDRevenue, FY2025: 43.77M USDOperating income, FY2021: −75.04M USDOperating income, FY2022: −89.15M USDOperating income, FY2023: −79.13M USDOperating income, FY2024: −60.58M USDOperating income, FY2025: −41.98M USDNet income, FY2021: −75.8M USDNet income, FY2022: −88.22M USDNet income, FY2023: −76.4M USDNet income, FY2024: −58.24M USDNet income, FY2025: −35.04M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 6.34M USD. Revenue FY2025 43.77M USD. Operating income FY2021 −75.04M USD. Operating income FY2022 −89.15M USD. Operating income FY2023 −79.13M USD. Operating income FY2024 −60.58M USD. Operating income FY2025 −41.98M USD. Net income FY2021 −75.8M USD. Net income FY2022 −88.22M USD. Net income FY2023 −76.4M USD. Net income FY2024 −58.24M USD. Net income FY2025 −35.04M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue43.77M USD6.34M USD———
Cost of goods sold1.54M USD———1.5M USD
Gross profit42.23M USD6.34M USD——−1.5M USD
Research and development56.04M USD41.21M USD52.14M USD59.2M USD51.19M USD
Selling, general, and administrative29.71M USD24.78M USD27M USD29.95M USD22.36M USD
Operating expenses84.21M USD66.93M USD79.13M USD89.15M USD73.55M USD
Interest income3.4M USD———600 USD
Interest expense—100K USD——600K USD
Depreciation and amortization1.54M USD1.64M USD1.9M USD1.85M USD1.5M USD
Operating income−41.98M USD−60.58M USD−79.13M USD−89.15M USD−75.04M USD
Net income−35.04M USD−58.24M USD−76.4M USD−88.22M USD−75.8M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-261.35%
11 comparable reports
Latest EPS result
-0.33
Estimate -0.59 · Beat by 44.07%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.09-1.17-2.24-3.32Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual -2.8, estimate -3.08, surprise +9.09%, Beat. Q2 2025, reported May 8, 2025: actual -2.52, estimate -0.11, surprise -2190.91%, Miss. Q3 2025, reported Aug 14, 2025: actual -2.24, estimate -1.12, surprise -100.00%, Miss. Q4 2025, reported Nov 13, 2025: actual -1.54, estimate -0.42, surprise -266.67%, Miss. Q1 2026, reported Mar 23, 2026: actual -0.85, estimate -1.68, surprise +49.40%, Beat. Q2 2026, reported May 12, 2026: actual -0.58, estimate -0.66, surprise +12.12%, Beat. Q3 2026, reported Aug 13, 2026: actual -0.33, estimate -0.59, surprise +44.07%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.82, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates20.45M14.12M7.79M1.47MQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual 1.72M USD, estimate 3.3M USD, surprise -47.76%, Miss. Q2 2025, reported May 8, 2025: actual 2.92M USD, estimate 4.4M USD, surprise -33.75%, Miss. Q3 2025, reported Aug 14, 2025: actual 8.09M USD, estimate 8.21M USD, surprise -1.46%, Miss. Q4 2025, reported Nov 13, 2025: actual 19.07M USD, estimate 18.64M USD, surprise +2.31%, Beat. Q1 2026, reported Mar 23, 2026: actual 13.69M USD, estimate 10.9M USD, surprise +25.60%, Beat. Q2 2026, reported May 12, 2026: actual 12.65M USD, estimate 8.52M USD, surprise +48.47%, Beat. Q3 2026, reported Aug 13, 2026: actual 18.69M USD, estimate 12.72M USD, surprise +46.95%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 4.84M USD, surprise —, Comparison unavailable.

XLO news

globenewswire.com

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs…

Read source
globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer,…

Read source
globenewswire.com

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer,…

Read source

Corporate actions

Corporate action history

Stock split

Effective Mar 16, 2026

1:14

XLO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$441.01

+0.38%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.17

+0.03%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.77

-0.05%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.6

-0.58%

Sanofi logo

SNY

Sanofi

$45.602

-0.54%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.38

-1.04%

ETFs holding XLO

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.3M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$377.72-0.14%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
324.37K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.69-0.75%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
76.86K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$197.26-0.44%
Dimensional - US Core Equity 1 ETF logoDimensional - US Core Equity 1 ETFDCOR
Market value
10.3K
Weight
0.00%
AUM
3.51B USD
Expense ratio
0.14%
Price / 1D
$84.465-0.09%
Dimensional - US Core Equity 2 ETF logoDimensional - US Core Equity 2 ETFDFAC
Market value
2.34K
Weight
0.00%
AUM
49.31B USD
Expense ratio
0.17%
Price / 1D
$45.515-0.21%

Continue in GoAI

Research XLO

research.disclaimer